Amlitelimab Reduces AD Symptoms in Phase 2b Trial

Treatment with amlitelimab, an anti-OX40 ligand antibody, significantly reduced symptoms of atopic dermatitis (AD) and was maintained even after treatment stopped in new research published in the Journal of Allergy and Clinical Immunology.

Results from the phase 2b STREAM-AD trial, evaluating amlitelimab in adult patients with moderate-to-severe atopic dermatitis, demonstrated amlitelimab’s potential to be an effective treatment option and support the viability of extended dosing every 12 weeks, which is currently being investigated in the robust phase 3 clinical trial program OCEANA.

In the STREAM-AD trial, amlitelimab significantly improved symptoms of AD, with most patients showing marked reductions in disease severity by Week 16, as measured by EASI and IGA scores. Clinical responses at Week 24 (Investigator Global Assessment 0/1 and/or EASI-75) were maintained at Week 52 in patients continuing or withdrawn from amlitelimab. Amlitelimab was well tolerated across all dose levels, with a low incidence of serious adverse events, making it a potentially safe, long-term option for managing moderate-to-severe AD.

“Durable maintenance of clinical response along with sustained reductions in Th2 and Th17/Th22 inflammatory biomarkers raise the possibility that amlitelimab may have normalized key drivers of inflammation in AD,” the authors wrote.